(Q46604896)

23 December 2017

title

Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care (English)

1 reference

23 December 2017

main subject

irritable bowel syndrome

1 reference

1 reference

Peter Layer

1

1 reference

23 December 2017

Jutta Keller

2

1 reference

23 December 2017

Stefan Mueller-Lissner

3

1 reference

23 December 2017

Peter Rüegg

4

1 reference

23 December 2017

Helena Loeffler

5

1 reference

23 December 2017

publication date

12 July 2005

1 reference

23 December 2017

published in

Digestion

1 reference

23 December 2017

volume

71

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

238-244

1 reference

23 December 2017

Management of the irritable bowel syndrome

cites work

1 reference

Epidemiological aspects of irritable bowel syndrome in Europe and North America.

21 January 2018

1 reference

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects

21 January 2018

1 reference

21 January 2018

1 reference

Irritable bowel syndrome in Germany. A cost of illness study.

21 January 2018

1 reference

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

21 January 2018

1 reference

Irritable bowel syndrome: evaluation and treatment

21 January 2018

1 reference

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects

21 January 2018

1 reference

Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects

21 January 2018

1 reference

Review article: tegaserod

21 January 2018

1 reference

Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation

21 January 2018

1 reference

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

21 January 2018

1 reference

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000087049

1 reference

23 December 2017

1 reference

23 December 2017